Table 2.
Estimated parameters of primary efficacy endpoint analysis.
| Parameter | Value | %RSE | 95% CI | Recommended dose |
|---|---|---|---|---|
| Oxycodone ED50 (mg/day) | 47.0 | 17.7 | (12.3, 179) | 20–160 mg/day |
| Oxymorphone ED50 (mg/day) | 83.9 | 15.0 | (22.9, 308) | 10–80 mg/day |
| Tramadol ED50 (mg/day) | 247 | 15.4 | (47.0, 1299) | 100–300 mg/day |
| Emax (mm) | −28.4 | 16.0 | (−37.3, −19.5) | - |
| PLC (mm) | −16.7 | 8.26 | (−19.4, −14.0) | - |
| ω2 of PLC | 0.0797 | 41.3 | (0.0152, 0.144) | - |
| σ2 | 0.0482 | 36.3 | (0.0139, 0.0825) | - |
%RSE = relative standard error.
95% CI = 95% confidence interval estimated by PDx-Pop®.